Two cyclic homopentapeptides, analogs of viomycin and capreomycin, respectively], were identified as novel antibacterial agents for the treatment of animal disease, especially for livestock respiratory disease. The in vitro microbiological characterization of both CP-101,680 and CP-163,234 was carried out using their parent compounds, viomycin and capreomycin, as controls. This characterization included antibacterial spectrum, influence of media, inoculum size, pH, EDTA, polymixin B nonapeptide (PMBN), serum, cell-free protein synthesis inhibition, and time-kill kinetics. Our results indicated that the capreomycin analog, CP-163,234, showed slightly improved in vitro potency over the viomycin analog, CP-101,680. Both analogs showed very potent cell-free protein synthesis inhibition activity and were bactericidal against Pasteurella haemolytica, P. multocida and Actinobacillus pleuropneumoniae at the level of 4 times and 8 times MICs. CP-163,234 was bactericidal at the level of4X and 8X MIC against E. coli, but re-growth was observed after 24 hours incubation at both concentrations of CP-1 01 ,680.
characterization included antibacterial spectrum, influence of media, inoculum size, pH, EDTA, polymixin B nonapeptide (PMBN), serum, cell-free protein synthesis inhibition, and time-kill kinetics. Our results indicated that the capreomycin analog, CP-163,234, showed slightly improved in vitro potency over the viomycin analog, CP-101,680. Both analogs showed very potent cell-free protein synthesis inhibition activity and were bactericidal against Pasteurella haemolytica, P. multocida and Actinobacillus pleuropneumoniae at the level of 4 times and 8 times MICs. CP-163,234 was bactericidal at the level of4X and 8X MIC against E. coli, but re-growth was observed after 24 hours incubation at both concentrations of CP-1 01 ,680. Viomycin (tuberactinomycin B) , marketed as a tuberculostatic agent in the 1960's, is a cyclic homopentapeptide containing the unusual amino acids viomycidine, hydroxyl j8-lysine, and /?-ureidodehydroalanine.
A more potent compound,capreomycin, discovered by Lilly1} in 1959 from fermentation of Streptomyces capreolus has a similar structure but is produced as a fourcomponent mixture, with capreomycin IA and IB present as major products, and IIA and IIB as minor products2). In recent years, the biosynthesis of capreomycin has been extensively studied by Gould, et al.3A\ Viomycin and capreomycin are primarily potent against Mycobacteria5\ with little activity against other bacteria. It has been reported that viomycin inhibits protein synthesis primarily by blocking the translocation of peptidyl-transfer RNA from the A to the P site of the bacterial ribosome6). A 6a- (3,4-dichlorophenylamino) analog of viomycin 680) was uncovered by a high throughput screen against the bovine pathogen Pasteurella haemolytica1^.
Subsequently, this structure served as a novel lead compound for both animal and human health infectious disease programs7 '8) . In the present paper, we describe in vitro microbiological pro filing of both CP-101,680 and its equivalent capreomycin (IA and IB mixture) analog, 234 , that was carried out as part of a program to assess clinical potential as antibacterial agents for livestock.
Materials and Methods

Bacterial Strains
The Sigma) were used.
The antibiotics used in this study were viomycin, capreomycin, CP-10 1 ,680 [6a-(3 ' ,4' -dichlorophenylamino) analog of viomycin], and 4 '-dichlorophenylamino) analog of capreomycin]. All antibiotics were supplied from the in-house collection. The chemical structures of these compoundsare presented in Fig. 1 . The synthetic method for both CP-101,680 and CP-163,234 is described in reference^.
In Vitro MIC Analysis
MICs (Minimum Inhibitory. Concentrations) were NOV. 1999 determined using a broth microdilution method described previously1 1}. All experiments were carried out in duplicate.
Anti-bacterial Spectrum Broth Microdilution Assay
The assay method was previously described11}. All experiments were carried out in duplicate.
Bactericidal Kinetics
Time-kill kinetic analysis was carried out by the method described12~14). Colony counts were performed with plates yielding 30 to 300 colonies. The lower limit of sensitivity of colony counts was 300 CFU/ml12).
Analysis for Various Factors Affecting In Vitro Potency
The influence of media, inoculum size, pH, EDTA, polymixin B nonapeptide (PMBN)and serum were carried out by the method described13). All experiments were carried out in duplicate.
In Vitro MS2 Directed Polypeptide Synthesis Inhibition Assay A cell-free translation system using S-150 derived from E. coli BL21 has been described previously15).
Results
Antibacterial Spectrum
The antibacterial spectrum results are presented in 
Bactericidal Kinetic Analysis
Time kill kinetics studies ofCP-101,680 and CP-163,234
were carried out at the levels of 4 times and 8 times the MICs; The 8X MIC results are presented in Fig. 2 for CP-101,680 and Fig. 3 for CP-163,234. Both cyclic peptides were bactericidal against P. haemolytica, P. multocida, A. pleuropneumoniae and E. coli at both 4times (data not shown) and 8 times the MIC. All four bacterial species were quickly killed during the initial 3hour exposure to antibiotics.
After 24hours, no bacterial re-growth was observed, except E. coli against CP-101 ,680.
Effect of Media, Cations and Inoculum Size
Both viomycin and capreomycin showed high MIC values (100~>200^g/ml) in various broths against four bacteria (Table  2) . CP-101,680 and CP-163,234 showed equivalent MICs in MH, BHI and LB broths and there was no significant media effect against bacterial strains tested except E. coli. MICs in MHbroth against E. coli showed 4-8times more potent activity than other broth media. Varying the inoculum size from 104 to 106cfu/ml was evaluated and showedno effect on the in vitro potency of viomycin, capreomycin, 234 against E. coli, P. haemolytica and P. multocida (data not shown). A. pleuropneumoniae showed a significant increase in sensitivity at the inoculum size 104 cfu/ml for all four test compounds compared to those of 105 and 106cfu/ml inoculum size (data not shown).
Effect of pH
Viomycin and capreomycin showed significantly improved potency against four bacterial strains tested in alkaline pH (Table 3) . P. haemolytica, and A. pleuropneumoniae, however did not grow in an acidic environment (Table  4) as described  previously13l  CP-101,680 and CP-163,234 were also more potent in alkaline conditions than in acidic conditions against E. coli and in neutral conditions against both P. haemolytica and A. pleuropneumoniae. MICswere highest, however, against P. multocida in neutral pH, followed by alkaline conditions with CP-101,680 and CP-163,234. All four compoundswere most potent in alkaline conditions.
Effect ofPMBN and EDTA PMBN showed antibacterial activity against P. haemolytica and A pleuropneumoniae (MIC 3.13 jUg/ml and 1.56 /ig/ml, respectively13^. Therefore, the highest concentration of PMBN tested against these bacteria was 1.0/ig/ml. In contrast, P. multocida and E. coli were moreresistant to PMBNthan P. haemolytica and A. pleuropneumoniae (MIC 800 /ig/ml and 200 /ig/ml, respectively13^and the highest concentration of PMBNtested was 50 /ig/ml. (Table 4) . The results of EDTAaddition to the test mediumare presented in Table 5 . P. haemolytica, P. multocida and A. pleuropneumoniae were sensitive to EDTA at the concentration of 0.5 mM13). Therefore these bacteria were tested at 0.1mM EDTA. This sub-MIC level of EDTA did not increase the potency of viomycin, capreomycin, CP-101,680 and CP-163,234 against P multocida and A.
pleuropneumoniae, and showed a slight increase in potency (2 fold) against P. haemolytica. The potency of CP-101,680 against E. coli increased in a dose dependent manner and a 4-fold increase in potency was observed in the presence of 0.5 mMEDTA.However, its parent compound, viomycin was not affected by the presence of EDTA (Table 5 ). In contrast to those, capreomycin and CP-163,234 showed2-to 4-fold potency increase in the presence of 0.5 mMEDTA but this increase was not dose dependent (Table 5) .
Effect of 40% Heat Inactivated Bovine Serum
MICresults of the addition of 40% heat inactivated bovine serum to the assay system in the presence and absence of 5% CO2are presented in Table 6 . The addition of serum to the growth mediumshifted the pH towards alkalinity during 18 hours incubation13). The potency of viomycin and capreomycin against the four bacterial species tested was not affected by either the addition of serum nor the presence of 5% CO2. However, MICs of 680 against all four bacterial species increased 2-to 4-fold with the addition of serum into the test medium.
In the presence of 5%CO2, these elevated MICs became much higher than in the absence of 5% CO2. These results indicate that there is a significant serum binding effect for CP-101,680. MICs ofCP-163,234 against the four bacterial species also increased in the presence of serum but no further MIC increase in the presence of 5% CO2was observed, except for A. pleuropneumoniae.
MS2 Directed Polypeptide Synthesis Inhibition Assay
The suggest that the improved antibacterial activity originates from the improvement of the molecules' intrinsic activity rather than transport through the outer membrane.This conclusion was further confirmed by the MIC results against the S. typhimurium LPS mutant and the effect of PMBN,which are discussed later.
Cell-free protein synthesis inhibition experiments also
showed that the IC50 of viomycin is significantly lower (100 times) than capreomycin (0.3^m vs. 20jiu). In contrast, both viomycin and capreomycin showed equivalent antibacterial activity against a panel of pathogens, although their MICs are very high (Table 1 ). This result seems to indicate that capreomycin has better transport through the inner (plasma) membrane than viomycin because neither the outer membrane transport or universal efflux pumpare the rate limiting factors (discussed later). Viomycin has a hydroxylmethyl group at C-9, a hydroxy group at the C-19 position, and a /3-lysine at the C-15 position. In contrast, capreomycin possesses a /3-lysine at the C-9 position, an amino group at C-15, and hydrogens at the C-19 position (Fig. 1 ). This structural difference may contribute to better inner (plasma) membranetransport for capreomycin.
However, the IC50 difference was totally abolished by the replacement of the urea group with a 3,4-dichlororphenyl group at the 6a position.
The susceptibility of both the E. coli mutant strain WEZ120, lacking the universal efflux system (AacrAB) which pumps out manyantibiotics and dyes from inside of cells, and its isogenic parent strain (W4680) were tested using CP-101,680, CP-163,234, viomycin, and capreomycin. Historically, antibiotics, which are a substrate of this universal pump, show significant differences in MICs (improvement of antibacterial activity) against the mutant strain compared to its parent9'1 U4). Viomycin, capreomycin, CP-101,680, and CP-163,234 did not show any differential activity against WEZ120and W4680 strains ( not show any differential activity against SGSC230strain, which indicates that the outer membraneis not the limiting factor for entry of these compounds into the cell (Table 1 ). This conclusion is further supported by the demonstration that PMBNdid not significantly decrease the MICs of these compounds against E. coli in the presence of sub-MIC levels (3.13/ig/ml to 1.56/*g/ml for CP-101,680 and 3.13 /xg/ml to 0.78/ig/ml for CP-163,234). PMBNis known to be an outer membrane disrupting agent and at sub-MIC levels, the addition of PMBN in culture significantly enhances the activity of hydrophobic antibiotics such as erythromycin A, tilmicosin and fusidic acid (25 /ig/ml to 0.39/ig/ml, 25//g/ml to 0.39/ig/ml, and >400/*g/ml to
1.56 /ig/ml, respectively)1^. It is also known from previous work that the addition of sub-MIC levels of PMBNto a culture does not show any synergistic effect with hydrophobic compounds against P. haemolytica, P. multocida and A. pleuropneumoniae, probably due to the difference in the outer membranestructure13). The same conclusion was obtained in the present study using 234 . It is also knownthat overnight incubation in the presence of 40%heat inactivated bovine serum shifts the mediumpH towards alkalinity and this pH shift significantly improves macrolide antibacterial activity. However, incubation in growth medium containing 40% bovine serum in the presence of 5% CO2 neutralizes this pH shift and antibacterial activity of macrolides in alkaline conditions was also neutralized13). CP-101,680, CP-163,234, viomycin and capreomycin showed improved potency in alkaline conditions as observed with macrolides. In contrast to the macrolides, their antibacterial activity was less potent in the presence of 40%bovine serum. This decreased antibacterial activity was further diminished by incubating the assay plates in the presence of,5% CO2. These results indicate that these compoundswere bound to serum protein and this NOV. 1999 protein-binding diminished their antibacterial activity. 680 and CP-163,234 showed bactericidal activity against P. haemolytica, P. multocida and A. pleuropneumoniae in time-kill kinetic analyses ( Fig. 2 and   3 ). All three bacterial species were quickly killed during the initial 3 hour exposure to antibiotics at 8X MICand no regrowth was observed. Identical results were obtained at 4X
MIC (data not shown). These results indicate that both compounds are very potent bactericidal agents. The E. coli response to both compounds was slightly different from others. CP-163,234 showed similar bactericidal activity againstE. coli at the level of both 4X and 8X MICs. E. coli was killed effectively during the initial 3hours drug exposure and there was no regrowth during the following 21hours (Fig. 3) . In contrast, regrowth of E. coli was observed at 24hours at both 4X (data not shown) and 8X
MIC of CP-101,680, although CP-101,68a showed excellent killing during the initial 6hours (Fig. 2) . These results indicate that CP-163,234 is a more potent bactericidal agent than CP-101 ,680 against E. coli. Overall, the novel analogs CP-101,680 and CP-163,234 are potent bactericidal agents against the four pathogens tested. Due to the very high MICs, the time-kill kinetic study of the parent compounds, viomycin and capreomycin, were not tested for the present paper. However, bactericidality of capreomycin was reported against Mycobacterium tuberculosis with low MBC/MICratiosl6\ M. tuberculosis is significantly sensitive to viomycin and capreomycin compared to other pathogenic bacteria.
In summary, our microbiological pro filing of CP-1 01 ,680 and CP-163,234 reveals the following points: 1) both compoundsdemonstrated excellent in vitro antibacterial spectrum against animal respiratory, enteric and mastitis pathogens with very potent cell-free protein synthesis inhibition activity; 2) neither compoundis a substrate of the universal efflux pump AcrA/B system and they can reach the target (ribosomes) without interference of the outer membrane barrier of Gram-negative bacteria;
3) both compounds are bactericidal agents with rapid killing activity; and 4) both compounds showed good in vivo activity in E. coli and P. multocida infection mice models by a subcutaneous (SC) route of administration (6-10 mg/kg)7), in spite of their serum protein binding ability. These attributes seem to indicate that both CP-101,680 and CP-163,234 could be novel antibacterial agents for livestock infectious disease therapy. -å -E. coli control, --å -E. coli 8X, -aef-P. haemolytica control, -aef-R haemolytica 8x, -^-p multocida control, -A-P-multocida §x, -D-A. pleuropneumonia control,
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